Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.
about
A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophreniaAn epidemiological study of concomitant use of Chinese medicine and antipsychotics in schizophrenic patients: implication for herb-drug interactionIdentification of targeted analyte clusters for studies of schizophrenia.Definitions and drivers of relapse in patients with schizophrenia: a systematic literature reviewPrevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.Relapse and hospitalization in patients with schizophrenia and bipolar disorder at the St Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia: a comparative quantitative cross-sectional studyMedication adherence among older adults with schizophrenia.Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trialGenetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population.A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with SchizophreniaPaliperidone: the evidence of its therapeutic value in schizophrenia.Poor response to treatment: beyond medication.Analysis of Adverse Drug Reactions of Atypical Antipsychotic Drugs in Psychiatry OPDA double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia.Integrated treatment to achieve functional recovery for first-episode psychosis.Homesick: residential and care patterns in patients with severe mental illnessQuetiapine: efficacy, tolerability and safety in schizophrenia.Factors that influence the prescription of antipsychotics for patients with schizophrenia in chinaReview of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.The case for long-acting antipsychotic agents in the post-CATIE era.Social functioning as an outcome measure in schizophrenia studies.Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studiesThe utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disordersUse of risperidone long-acting injectable in a rural border community clinic in southern californiaExpected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.Treating bipolar disorder in the primary care setting: the role of aripiprazole.Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine.A review on schizophrenia and relapse--a quest for user-friendly psychopharmacotherapy.Blood biomarker discovery in drug-free schizophrenia: the contributionof proteomics and multiplex immunoassays.Burden of illness of people with persistent symptoms of schizophrenia: A multinational cross-sectional study.Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone.Aripiprazole, a novel atypical antipsychotic drug.[Mental patients and their profile of compliance with psychopharmacological treatment].Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval.A descriptive, open-label, long-term follow-up survey of psychotic patients receiving risperidone long-acting injectable: Preliminary results.SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study.Long-acting risperidone in stable patients with schizoaffective disorder.Family intervention and health care costs for kansas medicaid patients with schizophrenia.Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study.
P2860
Q24794849-FA221249-405A-48BB-B134-3B029DA538C0Q28477174-55A43D9C-DE91-4B75-9EE9-FD47EA16B731Q30476776-3F8CD962-4959-4A60-9BD5-A2AF819C9B3DQ33589087-104A06DE-1095-4E47-BFE0-008465DCA40FQ33814003-215E3116-76FC-4998-8589-DD4CD1E55A4FQ33817913-264D2515-90B9-414F-BC9C-448E53EE6830Q33893240-EB8E5375-C3DD-49E0-A5DF-47A11A6194A0Q33898356-55614B6F-A790-4B48-B6F5-35D437ADF4C3Q34273450-2B2457BD-8287-40D0-B39A-BCE65308CD6AQ34444162-F559FDAE-27E2-40B9-B4A4-33F835707654Q34449894-E084E565-59B4-427B-93EF-E296162BA516Q35236765-D2DF9389-5D63-448E-B54E-773563452A54Q35732364-7C17A64C-43F8-4764-B676-42CCAA05DF6CQ35958805-ACF0071E-6A49-43AA-B6D6-7BABD9C75EBEQ36168720-54984707-0924-4DD4-A61C-70DC2F215769Q36212197-F7A4626B-DAF1-4D64-8DBB-33F5C7CCAD79Q36532142-15D834F0-9807-4155-BBFE-AEBB9F8CCF92Q36600672-84C07256-3C09-41D0-977A-0945F928F5BEQ36626247-08A7CD18-A1EB-4F72-9F4D-0C0EDB7A00DCQ36758680-4059FC5D-AD98-4E62-B05F-43C2C70B39D3Q36973846-3EA5735B-B3BB-4C96-94C1-5D63B04CEE74Q37042180-7DF4D2BF-DBB5-44F4-A83C-92163E5001CFQ37056209-704675E5-DBF1-4DAA-9896-3ECFC720A2BEQ37225867-67489D5D-994C-424D-A99F-545E8D815D0AQ37422493-3A0086D9-A7E8-4E97-8D26-A30E7C27854EQ37429721-D6A8F6CD-A847-4773-BDD5-F25334FED10AQ37760926-273053FB-6977-4449-A37E-AB01E36F73E0Q38233228-E6837DE2-6438-456C-B14B-2283E6EF33F5Q38807041-C253DB3B-28D5-4FD5-9F11-A4C11DF12C01Q38992595-F1FDD740-9B5A-4F82-A676-78FD3FFD1114Q40512185-9B649507-033D-438C-9F40-E455540AD464Q40527756-508C3DFC-58F9-4B69-8346-25E2052D2D84Q42169008-8C2FB31D-9731-4451-858A-DEEBB2904348Q42610530-FF630ED1-69B7-4DF2-B254-809C66D28408Q42665309-F5544E18-CB50-40F8-8EC4-2E05F00F5ECBQ44539666-D2E542CC-51AD-4316-8C78-8BCB81700F22Q45238699-97EBC0EC-B4A3-49BA-B168-DE315173C0B1Q46689239-2887855F-1D70-4587-B685-D14E3354AA94Q46828508-17054C73-3320-461F-8DC5-C01EA65F076CQ46917161-6888AE65-47E9-4211-8E92-3ED94FEDDC3D
P2860
Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Relapse and rehospitalisation ...... ond generation antipsychotics.
@ast
Relapse and rehospitalisation ...... ond generation antipsychotics.
@en
Relapse and rehospitalisation ...... ond generation antipsychotics.
@nl
type
label
Relapse and rehospitalisation ...... ond generation antipsychotics.
@ast
Relapse and rehospitalisation ...... ond generation antipsychotics.
@en
Relapse and rehospitalisation ...... ond generation antipsychotics.
@nl
prefLabel
Relapse and rehospitalisation ...... ond generation antipsychotics.
@ast
Relapse and rehospitalisation ...... ond generation antipsychotics.
@en
Relapse and rehospitalisation ...... ond generation antipsychotics.
@nl
P1433
P1476
Relapse and rehospitalisation ...... ond generation antipsychotics.
@en
P2093
Emily K Schuchart
John G Csernansky
P304
P356
10.2165/00023210-200216070-00004
P577
2002-01-01T00:00:00Z
P6179
1027093879